An interventional study of Whey protein isolate and Potato protein isolate in Appetite and General Nutritional Disorders, sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-06.
Sponsored by University of Westminster · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Insulin Resistance with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Insulin Resistance · United Kingdom.
Among the 106 studies in Insulin Resistance with a site in United Kingdom, this one is the 74th largest by enrollment of the 95 interventional ones that give a count, is one of 13 that started in 2018, is one of 76 with no phase, and was the 94th registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →7 of the 106 studies in Insulin Resistance with a site in United Kingdom are open now. Recruiting first, the newest first:
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18–85 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–70
Leeds Beckett University · Sites in United Kingdom
Ages 18–40
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Salah Snouda · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 5 · Phase 4 6
First in 2002; this study’s year is marked. 13 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 31 across the 95 interventional studies, 147 across the 11 observational. Of the 83 that completed or were terminated, 17 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 106 have an industry lead sponsor. The 10 most frequent:
University of Westminster is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
University of Westminster has 2 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
4 of the studies in Insulin Resistance with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07606872Salah SnoudaValidation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes | 2026-12 |
| NCT06463483Imperial College LondonAutomated Insulin Delivery in Adults With Advanced Kidney Disease | 2026-12-30 |
| NCT07945093King's College LondonDiabetes Insulin Self-Management Education (DIME) Web-based Application to Support People With Type 2 Diabetes (T2D) Starting Insulin in Hospital | 2027-06-09 |
| NCT07073781Leeds Beckett UniversityProbiotics, Cognition and Metabolic Health in Young Adults With Overweight or Obesity | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 106 studies in Insulin Resistance with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
INTRODUCTION: Global protein consumption has been increasing for decades due to changes in socio-economic demographics and consumer trends towards higher protein intake, which may be related to their health benefits in performance nutrition and appetite regulation. The additional intake of protein often occurs in the form of supplements. One of the main ingredients used in sports and weight loss supplements are animal-derived proteins such as whey, which are of high quality, containing all the essential amino acids required in human nutrition with a high absorption rate. However, whey protein has a high environmental footprint, and it may contribute to insulin resistance in susceptible groups (e.g. obese, T2DM, insulin resistant, or those with sarcopenic obesity).
Rice and potato protein isolates are high-quality plant proteins containing all essential amino acids comparably to whey protein. These plant-derived proteins may provide a more sustainable and accessible alternative to animal-derived proteins for appetite regulation and weight management.
Intervention study with three treatment groups in a randomised, single-blind, triple crossover design.
Study population: Healthy male participants will receive three different isocaloric and -volumetric protein shakes prepared using whey, rice and potato protein powders on different trial days with at least a one-week washout period apart.
Biological samples (blood and saliva samples) are collected at various time points during the visit. Blood samples are collected at baseline 10 min prior (T-10), then at 30 min (T30), 60 min (T60), 120 min (T120) and at 180 min (T180) after protein shake consumption. Saliva samples are collected at baseline (T-10), then at every 30 minutes following protein shake consumption (T30, T60, T90, T120, T150, T180). In addition, pertinent questionnaires Visual Analogue Scale [VAS] for the assessment of satiety and VAS for the assessment of protein shakes' perception will be collected at T-10, T30, T60, T90, T120, T150, T180 and at T0, respectively
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Whey protein isolate (45.5g total protein content)
Dietary Supplement: Whey protein isolate
Potato protein isolate (45.3g total protein content)
Dietary Supplement: Potato protein isolate
Rice protein isolate (45.5g total protein content)
Dietary Supplement: Rice protein isolate
Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the whey protein shake: * Tropicana Trop50 Orange Juice 207mL * Water 43 mL * Sucralose 0.5g The total energy 233.47Kcal. Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake. Other ingredients in the potato protein shake: * Tropicana Trop50 Orange Juice 250mL * Sucralose 0.5g The total energy 233.46Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the rice protein shake: * Tropicana Trop50 Orange Juice 183mL * Water 67mL * Sucralose 0.5g The total energy 233.43Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T-10)
Marker: glucose (mmol/L)
Time frame: Glucose measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T30)
Marker: glucose (mmol/L)
Time frame: Glucose measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T60)
Marker: glucose (mmol/L)
Time frame: Glucose measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T120)
Marker: glucose (mmol/L)
Time frame: Glucose measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T180)
Marker: glucose (mmol/L)
Time frame: Glucose measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T-10)
Marker: insulin (ng/mL)
Time frame: Insulin measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T30)
Marker: insulin (ng/mL)
Time frame: Insulin measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T60)
Marker: insulin (ng/mL)
Time frame: Insulin measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T120)
Marker: insulin (ng/mL)
Time frame: Insulin measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T180)
Marker: insulin (ng/mL)
Time frame: Insulin measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T-10)
Markers: glucagon-like peptide 1 (pM)
Time frame: Glucagon-like peptide 1 measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T30)
Markers: glucagon-like peptide 1 (pM)
Time frame: Glucagon-like peptide 1 measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T60)
Markers: glucagon-like peptide 1 (pM)
Time frame: Glucagon-like peptide 1 measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T120)
Markers: glucagon-like peptide 1 (pM)
Time frame: Glucagon-like peptide 1 measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T180)
Markers: glucagon-like peptide 1 (pM)
Time frame: Glucagon-like peptide 1 measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T-10)
Markers: peptide tyrosine tyrosine (pg/mL)
Time frame: Peptide tyrosine tyrosine measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T30)
Markers: peptide tyrosine tyrosine (pg/mL)
Time frame: Peptide tyrosine tyrosine measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T60)
Markers: peptide tyrosine tyrosine (pg/mL)
Time frame: Peptide tyrosine tyrosine measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T120)
Markers: peptide tyrosine tyrosine (pg/mL)
Time frame: Peptide tyrosine tyrosine measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T180)
Markers: peptide tyrosine tyrosine (pg/mL)
Time frame: Peptide tyrosine tyrosine measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T-10)
Markers: ghrelin (pg/mL)
Time frame: Ghrelin (pg/mL) measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T30)
Markers: ghrelin (pg/mL)
Time frame: Ghrelin (pg/mL) measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T60)
Markers: ghrelin (pg/mL)
Time frame: Ghrelin (pg/mL) measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T120)
Markers: ghrelin (pg/mL)
Time frame: Ghrelin (pg/mL) measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T180)
Markers: ghrelin (pg/mL)
Time frame: Ghrelin (pg/mL) measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T-10)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected immediately prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T30)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T60)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T90)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 90 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T120)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T150)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 150 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T180)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after protein shake consumption
To assess the perception of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO®
Subjective analysis including: Visual Analogue Scale for Palatability (VAS-P). Scores range from 0 to 100 (the higher the score the lower the palatability)
Time frame: VAS for Palatability collected immediately after protein shake consumption
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Feb 2021, 30 months.
Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 30 months is above that.
Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Whey Protein Isolate
University of Westminster